RxDoctor Payments Data

Tiffany George, MD

Hematology & Oncology · Weston, FLNPI 1780004283

Payments from drug & device makers

$5,959in general payments, 2019–2025

Across 265 payments — averaging $22.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • Pfizer$601
  • GSK$477
  • Merck$368
  • Novartis$281
  • AstraZeneca$278
  • plus $3K from 35 others

What the payments were for

  • Food & beverage$5,89299%
  • Education$671%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,959 in reported general payments places this provider in the 40th percentile of 694 hematology & oncology providers in Florida.

See all hematology & oncology providers in Florida

Medicare billing

Part B allowed, 2024
$52,384
Medicare patients
139
Services billed
495

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CabometyxCabozantinib S-Malate36$1,016,985
ErleadaApalutamide48$582,192
XtandiEnzalutamide29$407,578
OrgovyxRelugolix40$104,770
Abiraterone Acetate82$79,566
CreonLipase/Protease/Amylase11$14,257
Imatinib Mesylate15$1,864
Prochlorperazine Maleate49$923
Mirtazapine41$624
LoperamideLoperamide Hcl25$488
Oxycodone Hcl53$481
Prednisone129$475
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen16$349
Dexamethasone13$215
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen11$206

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada$1,114$582,19248 claims
Astellas Pharma US IncXtandi$124$407,57829 claims
AbbVieCreon$91$14,25711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 694 hematology & oncology providers in Florida.

Other hematology & oncology in Weston

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →